Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Stanford University

Status: Terminated

Conditions: Pancreatic Cancer

Treatments: Drug: Iohexol; Drug: Iodixanol; Procedure: Stereotactic body radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT01326364

SU-03182010-5282 (Other Identifier)

PANC0009

Details and patient eligibility

About

The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.

Enrollment: 6 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and
2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.

Exclusion criteria

1. are absolute contraindications to intravenous iodinated contrast or CT scan.